Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. PTC Therapeutics Inc shares valued at $3,620,895 were sold by Almstead Neil Gregory on Dec 02 ’24. At $52.06 per share, Almstead Neil Gregory sold 69,550 shares. The insider’s holdings dropped to 86,202 shares worth approximately $3.9 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Almstead Neil Gregory sold 2,060 shares, netting a total of over 107,063 in proceeds. Following the sale of shares at $51.97 each, the insider now holds 4,576 shares.
Before that, ZELDIS JEROME B had sold 24,000 shares from its account. In a trade valued at $1,235,897, the Director traded PTC Therapeutics Inc shares for $51.50 each. Upon closing the transaction, the insider’s holdings decreased to 24,000 shares, worth approximately $0.66 million.
As published in a research note from Morgan Stanley on December 13, 2024, PTC Therapeutics Inc [PTCT] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $67 from $45. Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in early December. Earlier on September 04, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for PTCT stock.
Analyzing PTCT Stock Performance
During the last five days, there has been a drop of approximately -4.46%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 64.19%. Shares of the company reached a 52-week high of $54.16 on 12/03/24 and a 52-week low of $23.58 on 02/13/24. A 50-day SMA is recorded $43.23, while a 200-day SMA reached $35.40. Nevertheless, trading volume fell to 0.58 million shares from 0.6 million shares the previous day.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
According to the 24-hour chart, there is a support level at 44.63, which, if violated, would cause prices to drop to 44.00. In the upper region, resistance lies at 46.22. The next price resistance is at 47.18. RSI (Relative Strength Index) is 48.55 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.41, which suggests the price will decrease in the coming days. Percent R is at 90.37%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
